Lineage Cell Therapeutics Inc (NYSE MKT:LCTX) — Stock Price
Lineage Cell Therapeutics Inc (NYSE MKT:LCTX) is currently trading at $1.30 USD, down 1.52% today. Over the past 52 weeks, shares have ranged between $1.01 and $1.96. This page tracks Lineage Cell Therapeutics Inc's live share price on the NYSE MKT exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Lineage Cell Therapeutics Inc (LCTX) total market value.
Lineage Cell Therapeutics Inc (LCTX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Lineage Cell Therapeutics Inc's daily closing share price and trading volume on the NYSE MKT exchange over the past year, giving a clear view of recent price momentum and liquidity.
Lineage Cell Therapeutics Inc Income Statement — Revenue, Profit & Earnings by Year
Lineage Cell Therapeutics Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $9.50 Million | $8.95 Million | $14.70 Million | $3.90 Million | $773.00K |
| Cost of Revenue | $334.00K | $671.00K | $728.00K | $1.43 Million | $385.00K |
| Gross Profit | $9.16 Million | $8.27 Million | $13.97 Million | $2.47 Million | $388.00K |
| Research & Development | $12.47 Million | $15.71 Million | $13.99 Million | $33.91 Million | $12.32 Million |
| SG&A | $18.17 Million | $17.30 Million | $22.51 Million | $18.21 Million | $15.57 Million |
| Total Operating Expenses | $30.64 Million | $33.01 Million | $36.49 Million | $51.68 Million | $26.84 Million |
| Operating Income | $-21.48 Million | $-24.73 Million | $-22.52 Million | $-49.21 Million | $-26.45 Million |
| EBITDA | $-20.87 Million | $-24.04 Million | $-21.79 Million | $-48.34 Million | $-24.41 Million |
| EBIT | $-21.48 Million | $-24.73 Million | $-22.52 Million | $-49.21 Million | $-26.45 Million |
| Interest Expense | — | — | $5.18 Million | $2.00K | $5.16 Million |
| Income Before Tax | $-18.58 Million | $-23.28 Million | $-25.81 Million | $-43.27 Million | $-21.92 Million |
| Income Tax Expense | $27.00K | $-1.80 Million | $541.00K | $-4.71 Million | $-1.24 Million |
| Net Income | $-18.61 Million | $-21.49 Million | $-26.27 Million | $-43.02 Million | $-20.65 Million |
Lineage Cell Therapeutics Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Lineage Cell Therapeutics Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $113.22 Million | $101.02 Million | $123.66 Million | $174.54 Million | $107.95 Million |
| Total Current Assets | $51.00 Million | $38.44 Million | $60.00 Million | $111.55 Million | $44.00 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $2.02 Million | $50.00K | $46.52 Million | $2.62 Million | $8.98 Million |
| Net Receivables | $638.00K | $745.00K | $297.00K | $50.84 Million | $4.00K |
| Inventory | — | — | $1.00 | — | — |
| Property, Plant & Equipment | — | — | $5.67 Million | $4.87 Million | $5.63 Million |
| Goodwill | $10.67 Million | $10.67 Million | $10.67 Million | $10.67 Million | $10.67 Million |
| Total Liabilities | $36.21 Million | $39.00 Million | $51.73 Million | $83.65 Million | $12.82 Million |
| Total Current Liabilities | $13.98 Million | $17.96 Million | $18.98 Million | $47.12 Million | $7.77 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-43.27 Million | $-32.49 Million | $-7.46 Million | $-52.94 Million | $-28.76 Million |
| Total Stockholder Equity | $78.38 Million | $63.42 Million | $73.34 Million | $92.22 Million | $96.20 Million |
| Retained Earnings | $-403.46 Million | $-384.86 Million | $-363.37 Million | $-337.10 Million | $-294.08 Million |
Lineage Cell Therapeutics Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Lineage Cell Therapeutics Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-23.09 Million | $-28.57 Million | $1.06 Million | $-23.56 Million | $-19.75 Million |
| Capital Expenditures | $565.00K | $674.00K | $413.00K | $354.00K | $64.00K |
| Free Cash Flow | $-23.66 Million | $-29.24 Million | $646.00K | $-23.91 Million | $-19.82 Million |
| Investing Cash Flow | $-2.31 Million | $46.45 Million | $-46.16 Million | $9.74 Million | $13.04 Million |
| Financing Cash Flow | $35.86 Million | $6.42 Million | $1.63 Million | $36.93 Million | $29.86 Million |
| Dividends Paid | — | $37.00K | — | $7.24 Million | $25.15 Million |
| Stock-Based Compensation | $5.08 Million | $4.64 Million | $4.29 Million | $3.52 Million | $2.23 Million |
| Depreciation | $609.00K | $692.00K | $727.00K | $873.00K | $2.04 Million |
| Change in Cash | $10.36 Million | $24.06 Million | $-44.34 Million | $23.09 Million | $23.09 Million |
Lineage Cell Therapeutics Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Lineage Cell Therapeutics Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 07, 2026 | 0.00 | -0.02 | +100.00% |
| Mar 05, 2026 | 0.00 | -0.05 | +100.00% |
| Nov 06, 2025 | -0.13 | -0.02 | -550.00% |
| Aug 12, 2025 | -0.13 | -0.03 | -333.33% |
| May 07, 2025 | -0.02 | -0.03 | +28.57% |
| Mar 05, 2025 | -0.01 | -0.03 | +66.67% |
| Nov 07, 2024 | -0.02 | -0.04 | +50.00% |
| Aug 08, 2024 | -0.03 | -0.05 | +40.00% |